Gene Kim, MD
Clinical Cardiac Electrophysiology · Torrance, CANPI 1194732925
Payments from drug & device makers
Across 417 payments — averaging $60.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$19K
- Medtronic$2K
- Novartis$611
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$496
- Johnson & Johnson$352
- AstraZeneca$293
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$16,96967%
- Travel & lodging$410%
- Food & beverage$8,12432%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 97 | $18,631 |
| Medtronic(2 entities) | 98 | $2,309 |
| Novartis | 50 | $611 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 25 | $496 |
| Johnson & Johnson | 21 | $352 |
| AstraZeneca | 16 | $293 |
| Cardiva Medical, Inc. | 7 | $285 |
| Abbott | 8 | $233 |
| Pfizer | 16 | $202 |
| Boehringer Ingelheim | 9 | $188 |
| Sanofi-aventis U.S. LLC | 12 | $182 |
| Amgen | 10 | $175 |
| E.r. Squibb & Sons, L.L.C. | 9 | $173 |
| Acutus Medical, Inc. | 1 | $141 |
| Atricure, Inc. | 5 | $130 |
| Novo Nordisk | 6 | $107 |
| Alnylam Pharmaceuticals Inc. | 4 | $90 |
| Kestra Medical Technology Services, Inc. | 4 | $85 |
| Biotronik Inc. | 2 | $60 |
| Bayer | 2 | $42 |
| Regeneron Healthcare Solutions, Inc. | 1 | $40 |
| Amarin Pharma, Inc. | 2 | $35 |
| Stryker | 1 | $35 |
| ZOLL Circulation Inc | 1 | $30 |
| Actelion Pharmaceuticals US, Inc. | 1 | $28 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $25 |
| Bausch Health US, LLC | 1 | $25 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Abiomed | 1 | $24 |
| Merck | 1 | $22 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Teleflex LLC | 1 | $20 |
| Terumo Medical Corporation | 1 | $17 |
| GE HealthCare | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EMBLEM$7,364
- GENERAL TACHY$2,250
- EMBLEM MRI S-ICD$2,250
- GENERAL EP$1,849
- EMBLEM S ICD ELECTRODE DELIVERY SYSTEM$1,500
- GENERAL BRADY$1,250
- Rhythmia Mapping System$627
- Micra$242
- Azure$207
- VIGILANT$148
- PulseSelect$132
How this compares
$25,141 in reported general payments places this provider in the 35th percentile of 290 clinical cardiac electrophysiology providers in California.
See all clinical cardiac electrophysiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 890 | $997,355 |
| XareltoRivaroxaban | 175 | $236,321 |
| EntrestoSacubitril/Valsartan | 130 | $131,408 |
| MultaqDronedarone Hcl | 19 | $33,646 |
| Repatha SureclickEvolocumab | 23 | $16,331 |
| JardianceEmpagliflozin | 14 | $13,568 |
| Mexiletine Hcl | 118 | $11,319 |
| FarxigaDapagliflozin Propanediol | 12 | $10,858 |
| Praluent PenAlirocumab | 12 | $9,430 |
| Flecainide Acetate | 186 | $9,051 |
| Amiodarone Hcl | 289 | $6,630 |
| PradaxaDabigatran Etexilate Mesylate | 11 | $6,055 |
| Metoprolol Succinate | 387 | $5,776 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 15 | $4,572 |
| Losartan Potassium | 236 | $3,104 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $202 | $997,355890 claims |
| Johnson & JohnsonXarelto | $352 | $236,321175 claims |
| NovartisEntresto | $611 | $131,408130 claims |
| Sanofi-aventis U.S. LLCMultaq | $182 | $33,64619 claims |
| Boehringer IngelheimJardiance, Pradaxa | $188 | $19,62325 claims |
| AstraZenecaFarxiga | $293 | $10,85812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 290 clinical cardiac electrophysiology providers in California.
Other clinical cardiac electrophysiology in Torrance
- Sang Yong JiTorrance$264K
- Matthew OstromTorrance$238K
- David KrummenSan Diego$7.3M
- Jonathan DukesVentura$2.9M
- Shephal DoshiSanta Monica$2.9M
- Arash AryanaSacramento$2.4M
- Marco PerezStanford$2.1M
- Rahul DoshiLos Angeles$2M
- Mayer RashtianPasadena$1.8M
- Rajesh BankerNewport Beach$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.